Risk Assessment in Adult T Cell Leukemia/Lymphoma Treated with Allogeneic Hematopoietic Stem Cell Transplantation

ATL Working Group of the Japan Society for Hematopoietic Cell Transplantation

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Disease status at allogeneic hematopoietic cell transplantation (HCT) is an important pretransplant prognostic factor of HCT in adult T cell leukemia/lymphoma (ATL); however, other prognostic factors, including comorbidities, were not predictive in small cohort analyses. Several scoring systems (HCT-specific comorbidity index [HCT-CI]/modified European Group for Blood and Marrow Transplantation risk score [mEBMT]) have been adopted to predict HCT outcomes in other hematologic malignancies. We retrospectively evaluated HCT-CI and mEBMT to predict nonrelapse mortality (NRM) in 824 ATL patients registered in the Japan Society for Hematopoietic Cell Transplantation TRUMP database, from 2008 until 2013. A higher HCT-CI was associated with greater NRM when comparing HCT-CI 0 versus HCT-CI 1 to 3 and HCT-CI 0 versus HCT-CI ≥ 4. A higher mEBMT score was not associated with higher NRM when comparing mEBMT 0 to 3 with 4 to 6. Because ATL patients are older and consequently at risk of additional complications, we developed an optimized prognostic index for ATL (ATL-HCT-PI) using known risk factors: age, HCT-CI, and donor–recipient sex combination. The ATL-HCT-PI scores effectively predicted the 2-year NRM (22.0%, 27.7%, and 44.4%, respectively). Therefore, the newly developed ATL-HCT-PI, in combination with other risk factors, is more useful for predicting NRM in HCT for ATL patients.

Original languageEnglish
Pages (from-to)832-839
Number of pages8
JournalBiology of Blood and Marrow Transplantation
Volume24
Issue number4
DOIs
Publication statusPublished - Apr 1 2018

Fingerprint

Adult T Cell Leukemia Lymphoma
Hematopoietic Stem Cell Transplantation
Cell Transplantation
Mortality
Comorbidity
Hematopoietic System
Hematologic Neoplasms

All Science Journal Classification (ASJC) codes

  • Hematology
  • Transplantation

Cite this

Risk Assessment in Adult T Cell Leukemia/Lymphoma Treated with Allogeneic Hematopoietic Stem Cell Transplantation. / ATL Working Group of the Japan Society for Hematopoietic Cell Transplantation.

In: Biology of Blood and Marrow Transplantation, Vol. 24, No. 4, 01.04.2018, p. 832-839.

Research output: Contribution to journalArticle

ATL Working Group of the Japan Society for Hematopoietic Cell Transplantation. / Risk Assessment in Adult T Cell Leukemia/Lymphoma Treated with Allogeneic Hematopoietic Stem Cell Transplantation. In: Biology of Blood and Marrow Transplantation. 2018 ; Vol. 24, No. 4. pp. 832-839.
@article{6842492312b74b23957b59559f397c3f,
title = "Risk Assessment in Adult T Cell Leukemia/Lymphoma Treated with Allogeneic Hematopoietic Stem Cell Transplantation",
abstract = "Disease status at allogeneic hematopoietic cell transplantation (HCT) is an important pretransplant prognostic factor of HCT in adult T cell leukemia/lymphoma (ATL); however, other prognostic factors, including comorbidities, were not predictive in small cohort analyses. Several scoring systems (HCT-specific comorbidity index [HCT-CI]/modified European Group for Blood and Marrow Transplantation risk score [mEBMT]) have been adopted to predict HCT outcomes in other hematologic malignancies. We retrospectively evaluated HCT-CI and mEBMT to predict nonrelapse mortality (NRM) in 824 ATL patients registered in the Japan Society for Hematopoietic Cell Transplantation TRUMP database, from 2008 until 2013. A higher HCT-CI was associated with greater NRM when comparing HCT-CI 0 versus HCT-CI 1 to 3 and HCT-CI 0 versus HCT-CI ≥ 4. A higher mEBMT score was not associated with higher NRM when comparing mEBMT 0 to 3 with 4 to 6. Because ATL patients are older and consequently at risk of additional complications, we developed an optimized prognostic index for ATL (ATL-HCT-PI) using known risk factors: age, HCT-CI, and donor–recipient sex combination. The ATL-HCT-PI scores effectively predicted the 2-year NRM (22.0{\%}, 27.7{\%}, and 44.4{\%}, respectively). Therefore, the newly developed ATL-HCT-PI, in combination with other risk factors, is more useful for predicting NRM in HCT for ATL patients.",
author = "{ATL Working Group of the Japan Society for Hematopoietic Cell Transplantation} and Makoto Yoshimitsu and Ryuji Tanosaki and Koji Kato and Takashi Ishida and Ilseung Choi and Yoshifusa Takatsuka and Takahiro Fukuda and Tetsuya Eto and Michihiro Hidaka and Naoyuki Uchida and Toshihiro Miyamoto and Yasuhiro Nakashima and Yukiyoshi Moriuchi and Koji Nagafuji and Yasuhiko Miyazaki and Tatsuo Ichinohe and Minoko Takanashi and Yoshiko Atsuta and Atae Utsunomiya",
year = "2018",
month = "4",
day = "1",
doi = "10.1016/j.bbmt.2017.11.005",
language = "English",
volume = "24",
pages = "832--839",
journal = "Biology of Blood and Marrow Transplantation",
issn = "1083-8791",
publisher = "Elsevier Inc.",
number = "4",

}

TY - JOUR

T1 - Risk Assessment in Adult T Cell Leukemia/Lymphoma Treated with Allogeneic Hematopoietic Stem Cell Transplantation

AU - ATL Working Group of the Japan Society for Hematopoietic Cell Transplantation

AU - Yoshimitsu, Makoto

AU - Tanosaki, Ryuji

AU - Kato, Koji

AU - Ishida, Takashi

AU - Choi, Ilseung

AU - Takatsuka, Yoshifusa

AU - Fukuda, Takahiro

AU - Eto, Tetsuya

AU - Hidaka, Michihiro

AU - Uchida, Naoyuki

AU - Miyamoto, Toshihiro

AU - Nakashima, Yasuhiro

AU - Moriuchi, Yukiyoshi

AU - Nagafuji, Koji

AU - Miyazaki, Yasuhiko

AU - Ichinohe, Tatsuo

AU - Takanashi, Minoko

AU - Atsuta, Yoshiko

AU - Utsunomiya, Atae

PY - 2018/4/1

Y1 - 2018/4/1

N2 - Disease status at allogeneic hematopoietic cell transplantation (HCT) is an important pretransplant prognostic factor of HCT in adult T cell leukemia/lymphoma (ATL); however, other prognostic factors, including comorbidities, were not predictive in small cohort analyses. Several scoring systems (HCT-specific comorbidity index [HCT-CI]/modified European Group for Blood and Marrow Transplantation risk score [mEBMT]) have been adopted to predict HCT outcomes in other hematologic malignancies. We retrospectively evaluated HCT-CI and mEBMT to predict nonrelapse mortality (NRM) in 824 ATL patients registered in the Japan Society for Hematopoietic Cell Transplantation TRUMP database, from 2008 until 2013. A higher HCT-CI was associated with greater NRM when comparing HCT-CI 0 versus HCT-CI 1 to 3 and HCT-CI 0 versus HCT-CI ≥ 4. A higher mEBMT score was not associated with higher NRM when comparing mEBMT 0 to 3 with 4 to 6. Because ATL patients are older and consequently at risk of additional complications, we developed an optimized prognostic index for ATL (ATL-HCT-PI) using known risk factors: age, HCT-CI, and donor–recipient sex combination. The ATL-HCT-PI scores effectively predicted the 2-year NRM (22.0%, 27.7%, and 44.4%, respectively). Therefore, the newly developed ATL-HCT-PI, in combination with other risk factors, is more useful for predicting NRM in HCT for ATL patients.

AB - Disease status at allogeneic hematopoietic cell transplantation (HCT) is an important pretransplant prognostic factor of HCT in adult T cell leukemia/lymphoma (ATL); however, other prognostic factors, including comorbidities, were not predictive in small cohort analyses. Several scoring systems (HCT-specific comorbidity index [HCT-CI]/modified European Group for Blood and Marrow Transplantation risk score [mEBMT]) have been adopted to predict HCT outcomes in other hematologic malignancies. We retrospectively evaluated HCT-CI and mEBMT to predict nonrelapse mortality (NRM) in 824 ATL patients registered in the Japan Society for Hematopoietic Cell Transplantation TRUMP database, from 2008 until 2013. A higher HCT-CI was associated with greater NRM when comparing HCT-CI 0 versus HCT-CI 1 to 3 and HCT-CI 0 versus HCT-CI ≥ 4. A higher mEBMT score was not associated with higher NRM when comparing mEBMT 0 to 3 with 4 to 6. Because ATL patients are older and consequently at risk of additional complications, we developed an optimized prognostic index for ATL (ATL-HCT-PI) using known risk factors: age, HCT-CI, and donor–recipient sex combination. The ATL-HCT-PI scores effectively predicted the 2-year NRM (22.0%, 27.7%, and 44.4%, respectively). Therefore, the newly developed ATL-HCT-PI, in combination with other risk factors, is more useful for predicting NRM in HCT for ATL patients.

UR - http://www.scopus.com/inward/record.url?scp=85039424663&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85039424663&partnerID=8YFLogxK

U2 - 10.1016/j.bbmt.2017.11.005

DO - 10.1016/j.bbmt.2017.11.005

M3 - Article

C2 - 29155320

AN - SCOPUS:85039424663

VL - 24

SP - 832

EP - 839

JO - Biology of Blood and Marrow Transplantation

JF - Biology of Blood and Marrow Transplantation

SN - 1083-8791

IS - 4

ER -